CN111592498A - [2-(5′-氟尿嘧啶)乙酸-二乙基二硫代氨基甲酸]酐及在制备抗癌药物中的应用 - Google Patents
[2-(5′-氟尿嘧啶)乙酸-二乙基二硫代氨基甲酸]酐及在制备抗癌药物中的应用 Download PDFInfo
- Publication number
- CN111592498A CN111592498A CN202010512237.3A CN202010512237A CN111592498A CN 111592498 A CN111592498 A CN 111592498A CN 202010512237 A CN202010512237 A CN 202010512237A CN 111592498 A CN111592498 A CN 111592498A
- Authority
- CN
- China
- Prior art keywords
- fluorouracil
- compound
- preparation
- anhydride
- acetic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000008064 anhydrides Chemical class 0.000 title claims abstract description 28
- 229960002949 fluorouracil Drugs 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 11
- 229940041181 antineoplastic drug Drugs 0.000 title abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 229940116901 diethyldithiocarbamate Drugs 0.000 claims abstract description 13
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 13
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229910001431 copper ion Inorganic materials 0.000 claims abstract description 9
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 15
- 230000001394 metastastic effect Effects 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 25
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract description 15
- 238000002474 experimental method Methods 0.000 abstract description 11
- 230000015572 biosynthetic process Effects 0.000 abstract description 10
- 230000000259 anti-tumor effect Effects 0.000 abstract description 9
- 231100000263 cytotoxicity test Toxicity 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- LMBWSYZSUOEYSN-UHFFFAOYSA-N diethyldithiocarbamic acid Chemical compound CCN(CC)C(S)=S LMBWSYZSUOEYSN-UHFFFAOYSA-N 0.000 abstract description 8
- 238000003786 synthesis reaction Methods 0.000 abstract description 7
- 238000013461 design Methods 0.000 abstract description 3
- -1 dithiocarbamate compound Chemical class 0.000 abstract description 3
- 230000004663 cell proliferation Effects 0.000 abstract description 2
- 239000012990 dithiocarbamate Substances 0.000 abstract description 2
- 229950004394 ditiocarb Drugs 0.000 abstract description 2
- 206010027476 Metastases Diseases 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 230000009401 metastasis Effects 0.000 abstract 2
- 238000001212 derivatisation Methods 0.000 abstract 1
- 239000002547 new drug Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000010949 copper Substances 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- CPMUSDZOVZYEJJ-UHFFFAOYSA-N 2-(5-fluoro-2,4-dioxopyrimidin-1-yl)acetic acid Chemical compound OC(=O)CN1C=C(F)C(=O)NC1=O CPMUSDZOVZYEJJ-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 239000012346 acetyl chloride Substances 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229940108925 copper gluconate Drugs 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229960002563 disulfiram Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000604027 Homo sapiens Nuclear protein localization protein 4 homolog Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100038438 Nuclear protein localization protein 4 homolog Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 101000693619 Starmerella bombicola Lactone esterase Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 150000004659 dithiocarbamates Chemical class 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000004073 vulcanization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010512237.3A CN111592498B (zh) | 2020-06-08 | 2020-06-08 | [2-(5′-氟尿嘧啶)乙酸-二乙基二硫代氨基甲酸]酐及在制备抗癌药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010512237.3A CN111592498B (zh) | 2020-06-08 | 2020-06-08 | [2-(5′-氟尿嘧啶)乙酸-二乙基二硫代氨基甲酸]酐及在制备抗癌药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111592498A true CN111592498A (zh) | 2020-08-28 |
CN111592498B CN111592498B (zh) | 2021-04-23 |
Family
ID=72179891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010512237.3A Active CN111592498B (zh) | 2020-06-08 | 2020-06-08 | [2-(5′-氟尿嘧啶)乙酸-二乙基二硫代氨基甲酸]酐及在制备抗癌药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111592498B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114656382A (zh) * | 2022-03-29 | 2022-06-24 | 湖南工程学院 | 光响应二乙基二硫代氨基甲酸酯前体分子及其制备方法和应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1969820A (zh) * | 2006-12-12 | 2007-05-30 | 济南帅华医药科技有限公司 | 抗癌药物组合物 |
US20100166881A1 (en) * | 2005-10-27 | 2010-07-01 | Prendergast George C | Novel IDO Inhibitors and Methods of Use Thereof |
CN102391191A (zh) * | 2011-09-01 | 2012-03-28 | 首都师范大学 | 2,4-二氨基喹唑啉的哌嗪二硫代甲酸酯衍生物及其制备方法和抗肿瘤用途 |
CN107226789A (zh) * | 2017-05-09 | 2017-10-03 | 北京大学 | 氨基二硫代甲酸酯类化合物、其制备方法以及在制备抗肿瘤药物中的用途 |
CN109232477A (zh) * | 2018-10-29 | 2019-01-18 | 郑州大学 | 查尔酮-氨基二硫代甲酸酯类过氧化氢酶抑制剂及其合成方法和应用 |
CN110330474A (zh) * | 2019-07-11 | 2019-10-15 | 北京师范大学 | 芹菜素-二硫代氨基甲酸酯类衍生物制备及抗肿瘤应用 |
-
2020
- 2020-06-08 CN CN202010512237.3A patent/CN111592498B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100166881A1 (en) * | 2005-10-27 | 2010-07-01 | Prendergast George C | Novel IDO Inhibitors and Methods of Use Thereof |
CN1969820A (zh) * | 2006-12-12 | 2007-05-30 | 济南帅华医药科技有限公司 | 抗癌药物组合物 |
CN102391191A (zh) * | 2011-09-01 | 2012-03-28 | 首都师范大学 | 2,4-二氨基喹唑啉的哌嗪二硫代甲酸酯衍生物及其制备方法和抗肿瘤用途 |
CN107226789A (zh) * | 2017-05-09 | 2017-10-03 | 北京大学 | 氨基二硫代甲酸酯类化合物、其制备方法以及在制备抗肿瘤药物中的用途 |
CN109232477A (zh) * | 2018-10-29 | 2019-01-18 | 郑州大学 | 查尔酮-氨基二硫代甲酸酯类过氧化氢酶抑制剂及其合成方法和应用 |
CN110330474A (zh) * | 2019-07-11 | 2019-10-15 | 北京师范大学 | 芹菜素-二硫代氨基甲酸酯类衍生物制备及抗肿瘤应用 |
Non-Patent Citations (2)
Title |
---|
ALFREDO GINER-SOROLLA等: "Synthesis and properties of 5-mercaptomethyluracil and related derivatives", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
苗艳: "新型香豆素衍生物的合成与抗增殖活性研究", 《华中师范大学硕士学位论文》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114656382A (zh) * | 2022-03-29 | 2022-06-24 | 湖南工程学院 | 光响应二乙基二硫代氨基甲酸酯前体分子及其制备方法和应用 |
CN114656382B (zh) * | 2022-03-29 | 2022-11-15 | 湖南工程学院 | 光响应二乙基二硫代氨基甲酸酯前体分子及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN111592498B (zh) | 2021-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104558093B (zh) | C21甾体皂苷苷元衍生物、其制备方法及其在制备抗肿瘤药物中的应用 | |
CN110713500B (zh) | 以2-苯甲酰吡啶缩氨基硫脲的钯配合物及其合成方法 | |
CN107629089A (zh) | 高活性的他克林‑铂(ii)配合物及其合成方法和应用 | |
Yang et al. | Improvement in the anticancer activity of 6-mercaptopurine via combination with bismuth (III) | |
WO2022170893A1 (zh) | 一种含氮芥的三联吡啶铁/钌配合物、合成方法与应用 | |
CN111592498B (zh) | [2-(5′-氟尿嘧啶)乙酸-二乙基二硫代氨基甲酸]酐及在制备抗癌药物中的应用 | |
CN111072725B (zh) | 一种具有萘普生四价铂结构的化合物、制备方法及其在制备抗肿瘤药物中的应用 | |
CN104774221A (zh) | 喹啉酮衍生物的金属配合物及其合成方法及应用 | |
CN104558094A (zh) | 皂苷苷元衍生物、其制备方法及在制备抗肿瘤药物中的应用 | |
CN107417580A (zh) | 一类具有抗肿瘤活性的棉酚‑l‑精氨酸席夫碱类化合物及其合成方法 | |
CN108558936B (zh) | 一种六钒酸-l-丙氨酸甲酯衍生物及其制备方法与应用 | |
CN111825623B (zh) | [2-(5′-氟尿嘧啶)乙酸-(n-乙基)哌嗪基二硫代氨基甲酸]酐及其应用 | |
CN107573318A (zh) | 一种具抗肿瘤活性的新型棉酚席夫碱类衍生物及其合成方法 | |
CN111518037B (zh) | [2-(5′-氟尿嘧啶)乙酸-乙基苯基二硫代氨基甲酸]酐及在制备抗癌药物中的应用 | |
CN104725431B (zh) | 喹啉酮衍生物的钴(ⅱ)配合物及其合成方法及应用 | |
CN112125925B (zh) | 抗肿瘤化合物噻唑烷酮双核铜化合物的制备方法 | |
CN111662237B (zh) | [2-(5′-氟尿嘧啶)乙酸-吡咯烷基二硫代氨基甲酸]酐及在制备抗癌药物中的应用 | |
CN102786458B (zh) | 吡咯甲酰胺衍生物、其制备方法和用途 | |
CN105037265A (zh) | 一类含查尔酮骨架的喹啉酮衍生物的制备方法及在抗癌药物中的应用 | |
CN109438525B (zh) | 具有化疗和光疗抗肿瘤作用的化合物及其制备方法和应用 | |
CN104804066A (zh) | 新型抗癌化合物、其制备方法以及制备抗癌药物的用途 | |
CN110183471B (zh) | 一种哌嗪类衍生物及制备方法及应用 | |
CN104804064A (zh) | 含萘环骨架的二氢吡唑氧肟酸c21甾体皂苷苷元衍生物及其制备方法与应用 | |
CN104861026A (zh) | 含呋喃骨架的二氢吡唑氧肟酸c21甾体皂苷苷元衍生物、其制备方法及应用 | |
CN106588716B (zh) | O-苯磺酰-4-三氟甲基水杨酰胺类化合物及其在制备抗肺癌药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20200828 Assignee: WUHAN MADESIN PHARMACEUTICAL TECHNOLOGY CO.,LTD. Assignor: HUBEI University OF TECHNOLOGY Contract record no.: X2023980047209 Denomination of invention: [2- (5 '- fluorouracil) acetic acid diethyldithiocarbamate] anhydride and its application in the preparation of anticancer drugs Granted publication date: 20210423 License type: Common License Record date: 20231121 Application publication date: 20200828 Assignee: TAILITE MEDICINE (HUBEI) CO.,LTD. Assignor: HUBEI University OF TECHNOLOGY Contract record no.: X2023980047204 Denomination of invention: [2- (5 '- fluorouracil) acetic acid diethyldithiocarbamate] anhydride and its application in the preparation of anticancer drugs Granted publication date: 20210423 License type: Common License Record date: 20231120 |
|
EE01 | Entry into force of recordation of patent licensing contract |